Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115424 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Hiroshi Imaoka und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: hiimaoka@east.ncc.go.j…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tegafur, Irinotecan, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Servier Institute, Servier.
Abstract (Originalsprache)
BACKGROUND: Liposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) improves survival in gemcitabine-refractory metastatic pancreatic cancer (PC) but requires a central venous port. S-1, an oral fluoropyrimidine with proven efficacy in PC, may replace 5-FU/LV in nal-IRI plus 5-FU/LV, potentially enhancing both convenience and antitumor effect. METHODS: This single-arm, open-label, phase 1/2 study included patients with histologically or cytologically confirmed adenocarcinoma, aged 20-80 years, an Eastern Cooperative Oncology Group performance status of 0-1, with metastatic disease, and refractory to gemcitabine-based treatment. The primary endpoint in phase 1 part was the frequency of dose-limiting toxicity (DLT) to nal-IRI plus S-1. The primary endpoint in phase 2 part was overall survival. This trial was registered in the Japan Registry of Clinical Trials database (jRCTs031210040). RESULTS: In phase 1 part, one patient with DLT was observed at nal-IRI 70 mg/m2 (day 1) with S-1 80 mg/m2/day (day 1-7) in a 2-week cycle, establishing this as the recommended phase 2 dose (RP2D). Forty-nine patients from phase 1 (n = 6) and phase 2 part (n = 43) were treated with the RP2D, and their results were pooled. Median overall survival was 10.3 months (95 % confidence interval, 8.1-12.0 months). A confirmed partial response was achieved in 10 patients (20.4 %). The most frequent treatment-emergent adverse events were hypoalbuminemia (98.0 %), anemia (98.0 %), and anorexia (81.6 %). There were no treatment-related deaths. CONCLUSIONS: This study demonstrated that nal-IRI plus S-1 exhibited promising efficacy and an acceptable safety profile in patients with metastatic PC refractory to gemcitabine-based treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: hiimaoka@east.ncc.go.jp.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
- Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Förderung
- Servier Institute
- Servier
Zitieren
APA
Imaoka, H., Ikeda, M., Ozaka, M., Oshima, K., Okano, N., Shimizu, S., Tsumura, H., Komatsu, Y., Yamashita, T., Kataoka, S., Nagano, H., Hisano, T., Sasaki, M., Kobayashi, S., Fukushima, T., Mitsunaga, S., Furukawa, T., Hamauchi, S., Ueno, M., & Furuse, J. (2025). Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115424
Vancouver
Imaoka H, Ikeda M, Ozaka M, Oshima K, Okano N, Shimizu S, et al. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115424
BibTeX
@article{Imaoka2025,
author = {Imaoka, Hiroshi and Ikeda, Masafumi and Ozaka, Masato and Oshima, Kotoe and Okano, Naohiro and Shimizu, Satoshi and Tsumura, Hidetaka and Komatsu, Yoshito and Yamashita, Taro and Kataoka, Shigeki and Nagano, Hiroaki and Hisano, Terumasa and Sasaki, Mitsuhito and Kobayashi, Satoshi and Fukushima, Taito and Mitsunaga, Shuichi and Furukawa, Takaaki and Hamauchi, Satoshi and Ueno, Makoto and Furuse, Junji},
title = {Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115424}
}
EUVIMED